NYLIM
BIIB icon

New York Life Investment Management’s Biogen BIIB Stock Holding History

New York Life Investment Management’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.76M Buy
22,013
+108
+0.5% +$20.7K 0.03% 358
2026
Q1 		$4.02M Buy
21,905
+595
+3% +$110K 0.03% 375
2025
Q4 		$3.75M Sell
21,310
-174
-0.8% -$28.4K 0.03% 378
2025
Q3 		$3.01M Sell
21,484
-852
-4% -$115K 0.03% 450
2025
Q2 		$2.81M Buy
22,336
+67
+0.3% +$8.35K 0.03% 457
2025
Q1 		$3.05M Sell
22,269
-189
-0.8% -$27K 0.03% 436
2024
Q4 		$3.43M Sell
22,458
-124
-0.5% -$20.9K 0.03% 419
2024
Q3 		$4.38M Sell
22,582
-385
-2% -$80.5K 0.04% 384
2024
Q2 		$5.32M Buy
22,967
+339
+1% +$73.7K 0.05% 319
2024
Q1 		$4.88M Sell
22,628
-690
-3% -$162K 0.05% 346
2023
Q4 		$6.03M Sell
23,318
-8,777
-27% -$2.16M 0.06% 273
2023
Q3 		$8.25M Sell
32,095
-1,195
-4% -$320K 0.09% 205
2023
Q2 		$9.48M Sell
33,290
-311
-0.9% -$92.6K 0.1% 193
2023
Q1 		$9.34M Buy
33,601
+10,028
+43% +$2.77M 0.1% 200
2022
Q4 		$6.53M Sell
23,573
-561
-2% -$158K 0.07% 262
2022
Q3 		$6.44M Sell
24,134
-398
-2% -$84.5K 0.08% 253
2022
Q2 		$5M Buy
+24,532
New +$5.01M 0.06% 308

Other funds holding BIIB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Amundi
Amundi Paris, France $413B AUM 44.57% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

New York Life Investment Management's BIIB Position: Q2 2026 in Review

New York Life Investment Management increased its Biogen (BIIB) stake by 0.49% in Q2 2026, buying an estimated $20.7K and bringing the position to 22,013 shares worth $4.76M. The position accounts for 0.03% of the portfolio, ranked #358.

New York Life Investment Management first reported a position in BIIB in Q2 2022 and has held it in 17 quarters since. The position peaked at $9.48M in Q2 2023. 765 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

  • New York Life Investment Management held 22,013 shares of Biogen worth $4.76M as of Q2 2026.
  • New York Life Investment Management bought 108 Biogen shares in Q2 2026, an estimated $20.7K.
  • Biogen made up 0.03% of New York Life Investment Management's portfolio in Q2 2026, its #358 holding.
  • New York Life Investment Management first reported a position in Biogen in Q2 2022 and has held it in 17 quarters since.
  • New York Life Investment Management's Biogen position peaked at $9.48M in Q2 2023.
  • 765 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on New York Life Investment Management's 13F filing for Q2 2026, filed 10 Aug 2026.